Concepedia

Els Lierman

EL

10

Publications

631

Citations

10

H-Index

2006

Active since

Affiliations

KU Leuven(Current)

AZ Sint-Jan

Els Lierman is an author at KU Leuven specializing in medicine, pathology, and tumor biology.

Top concepts

Publications per year

2006–2019

10

Publications

10

Sorafenib is a potent inhibitor of FIP1L1-PDGFRα and the imatinib-resistant FIP1L1-PDGFRα T674I mutant

Els Lierman, Cedric Folens, Elizabeth H. Stover et al. · Blood · 2006 · 132 citations · Full text

FIP1L1-PDGFRα D842V, a novel panresistant mutant, emerging after treatment of FIP1L1-PDGFRα T674I eosinophilic leukemia with single agent sorafenib

Els Lierman, Lucienne Michaux, E Beullens et al. · Leukemia · 2009 · 127 citations

, , +7

The ability of sorafenib to inhibit oncogenic PDGFR  and FLT3 mutants and overcome resistance to other small molecule inhibitors

Els Lierman, Idoya Lahortiga, Helen Van Miegroet et al. · Haematologica · 2007 · 93 citations · Full text

Analysis of phenotype and outcome in essential thrombocythemia with CALR or JAK2 mutations

Carla Al Assaf, Florence Van Obbergh, Johan Billiet et al. · Haematologica · 2015 · 63 citations · Full text

, , +18

The kinase inhibitor TKI258 is active against the novel CUX1-FGFR1 fusion detected in a patient with T-lymphoblastic leukemia/lymphoma and t(7;8)(q22;p11)

Bartosz Wasąg, Els Lierman, Jan Cools et al. · Haematologica · 2011 · 61 citations · Full text

Rows per page

1–5 of 10